Shahram Taeb

Shahram Taeb

Auto-generated profile, based on publicly available information

Shahram Taeb

Department of Radiology, School of Paramedical Sciences, Guilan University of Medical Sciences, Rasht, Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SMSahar Mafi
Sahar Mafi
EAElham Ahmadi
Elham Ahmadi
EMEileen Meehan
Eileen Meehan
Catharina ChiariCatharina Chiari
Catharina Chiari
BMBehzad Mansoori
Behzad Mansoori
Davood RostamzadehDavood Rostamzadeh
Davood Rostamzadeh
The mTOR complex 1 (mTORC1) coordinates several important environmental and intracellular cues to control a variety of biological processes, such as cell growth, survival, autophagy, and metabolism, in response to energy levels, growth signals, and nutrients. The endoplasmic reticulum (ER) is a crucial intracellular organelle that is essential for numerous cellular functions, including the synthesis, folding, and modification of newly synthesized proteins, stress responsiveness, and maintainence of cellular homeostasis. mTOR-mediated upregulation of protein synthesis induces the accumulation of misfolded or unfolded proteins in the ER lumen, which induces ER stress, leading to activation of the unfolded protein response (UPR) pathway. Reciprocally, ER stress regulates the PI3K/AKT/mTOR signaling pathway. Therefore, under pathologic conditions, the cross-talk between the mTOR and UPR signaling pathways during cellular stress can critically affect cancer cell fate and may be involved in the pathogenesis and therapeutic outcome of cancer. Here, we discuss accumulating evidence showing the mechanism of action, interconnections, and molecular links between mTOR signaling and ER stress in tumorigenesis and highlights potential therapeutic implications for numerous cancers.

1 March 2024 in Current Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
NSNasrin Seyedpour
Nasrin Seyedpour
EMElahe Motevaseli
Elahe Motevaseli
STShahram Taeb
Shahram Taeb
ANAzin Nowrouzi
Azin Nowrouzi
FMFatemeh Mirzaei
Fatemeh Mirzaei
MNMasoud Najafi
Masoud Najafi
Aim: This study investigated the protective effects of three antioxidants on radiationinduced lung injury. Background: Oxidative stress is one of the key outcomes of radiotherapy in normal tissues. It can induce severe injuries in lung tissue, which may lead to pneumonitis and fibrosis. Recently, interest in natural chemicals as possible radioprotectors has increased due to their reduced toxicity, cheaper price, and other advantages. Objective: The present study was undertaken to evaluate the radioprotective effect of Alpha-lipoic Acid (LA), Resveratrol (RVT), and Apigenin (APG) against histopathological changes and oxidative damage and survival induced by ionizing radiation (IR) in the lung tissues of rats. Methods: First, the lung tissue of 50 mature male Wistar rats underwent an 18 Gy gamma irradiation. Next, the rats were sacrificed and transverse sections were obtained from the lung tissues and stained with hematoxylin and eosin (H and E) and Mason trichrome (MTC) for histopathological evaluation. Then, the activity of Glutathione peroxidase (GPx), Superoxide Dismutase (SOD), and Malondialdehyde (MDA) was measured by an ELISA reader at 340, 405, and 550 nm. Results: Based on the results of this study, IR led to a remarkable increase in morphological changes in the lung. However, APG, RVT, and LA could ameliorate the deleterious effects of IR in lung tissue. IR causes an increase in GPX level, and APG+IR administration causes a decrease in the level of GPX compared to the control group. Also, the results of this study showed that RVT has significant effects in reducing MDA levels in the short term. In addition, compared to the control group, IR and RVT+IR decrease the activity of SOD in the long term in the lung tissues of rats. Also, the analysis of results showed that weight changes in IR, LA+IR, APG+IR, and control groups were statistically significant. Conclusion: APG and RVT could prevent tissue damage induced by radiation effects in rat lung tissues. Hence, APG, LA, and RVT could provide a novel preventive action with their potential antioxidant anti-inflammatory properties, as well as their great safety characteristic.

1 January 2024 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
STShahram Taeb
Shahram Taeb
Davood RostamzadehDavood Rostamzadeh
Davood Rostamzadeh
SMSahar Mafi
Sahar Mafi
Mohammad MofattehMohammad Mofatteh
Mohammad Mofatteh
Ali ZarrabiAli Zarrabi
Ali Zarrabi
MNMasoud Najafi
Masoud Najafi
The idea of cancer immunotherapy has spread, and it has made tremendous progress with the advancement of new technology. Immunotherapy, which serves to assist the natural defenses of the body in eradicating cancerous cells, is a remarkable achievement that has revolutionized both cancer research and cancer treatments. Currently, the use of stem cells in immunotherapy is widespread and shares a special characteristic, including cancer cell migration, bioactive component release, and immunosuppressive activity. In the context of cancer, mesenchymal stem cells (MSCs) are rapidly being identified as vital stromal regulators of tumor progression. MSCs therapy has been implicated in treating a wide range of diseases, including bone damage, autoimmune diseases, and particularly hematopoietic abnormalities, providing stem cell-based therapy with an extra dimension. Moreover, the implication of MSCs does not have ethical concerns, and the complications known in pluripotent and totipotent stem cells are less common in MSCs. MSCs have a lot of distinctive characteristics that, when coupled, make them excellent for cellular-based immunotherapy and as vehicles for gene and drug delivery in a variety of inflammations and malignancies. MSCs can migrate to the inflammatory site and exert immunomodulatory responses via cell-to-cell contacts with lymphocytes by generating soluble substances. In the current review, we discuss the most recent research on the immunological characteristics of MSCs, their use as immunomodulatory carriers, techniques for approving MSCs to adjust their immunological contour, and their usages as vehicles for delivering therapeutic as well as drugs and genes engineered to destroy tumor cells.

24 November 2025
Verified
Other
Open access
SMSahar Mafi
Sahar Mafi
EAElham Ahmadi
Elham Ahmadi
EMEileen Meehan
Eileen Meehan
Catharina ChiariCatharina Chiari
Catharina Chiari
BMBehzad Mansoori
Behzad Mansoori
Davood RostamzadehDavood Rostamzadeh
Davood Rostamzadeh
Supplementary Fig. S1. The structure of mTOR complexes and overview of the PI3K/AKT/mTOR signaling pathway. The mTOR signaling pathway is implicated in a variety of major cellular processes, from cell growth to apoptosis. mTOR nucleates at least two distinct multi-protein complexes, mTORC1 and mTORC2. mTORC1 activation occurs in the response of growth factors through PI3K/Akt and RAS/MAPK pathways. Human mTOR can assemble at least two larges, physically, and functionally distinct polyprotein complexes, mTORC1, and mTORC2. mTORC1 and mTORC2 share several common proteins, including the catalytic subunit mTOR, mLST8 and DEPTOR, and Tel2/Tti1 complex. In addition, each complex has specific proteins. The activity of mTORC1 is regulated by multiple signals, including nutrient availability such as amino acids (leucine, arginine, and glutamine), intracellular energy level (Low ATP/High AMP), and extracellular growth factors such as insulin and cytokine receptors. A receptor-mediated activation of PI3K leads to PIP3 being produced from PIP2. PIP3 then promoted the recruitment of PDK1, AKT, and mTORC2 complex, facilitating the phosphorylation and full activation of AKT at Thr308 and Ser473 via PDK1 and mTORC2, respectively. Activated AKT phosphorylates TSC2 and induces the dissociation of TSC1 and TSC2 complex, which results in the dissociation of TSC2 from lysosomes and loss of their inhibitory action on RHEB/mTORC1 axis. Upon activation, mTOC1 promotes basic cellular events, including Cap-dependent translation, fatty acid synthesis, nucleoid acid synthesis, ribosomal biogenesis, metabolic reprogramming to support rapid cancer cell growth and survival, metastasis and invasion, and angiogenesis. mTORC2 has different subcellular localization and phosphorylates and activates AGC kinase family members, including AKT at Ser473 (AKT-pSer473), SGK, and PKC in response to upstream signals such as IGF1. Similar to mTORC1, PI3K acts as a critical regulator of mTORC2 by inducing the binding of mTORC2 to the ribosome. mTOR, mammalian/mechanistic target of rapamycin; PI3K, phosphatidylinositol 3-kinase; RAPTOR, Regulatory associated protein of mTOR; PRAS40, Proline-rich AKT substrate 40ku; mLST8, Mammalian LST8, also called G protein b-subunit like protein; DEPTOR, DEP domain-containing-mTOR interacting protein; Tel2, Telomere maintenance 2; Tti1, Tel2-interacting protein 1; RICTOR, Rapamycin insensitive companion of mTOR; mSIN1, mitogen-activated protein kinase-associated protein 1; PROTOR, Protein observed with Rictor; SGK, serum glucose kinase; PKC, protein kinase C; IGF1; Insulin-like growth factor 1; AMPK, AMP-activated protein kinase; REDD1, regulated in development and DNA damage response 1; HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; PTEN, phosphatase and tensin homolog deleted on chromosome 10; NF-κB, nuclear factor-κB; ULK1, UNC-51-like kinase 1; 4E-BP1, initiation factor 4E-binding protein 1; RHEB, Ras homolog enriched in brain; TSC1 and TSC2, tuberous sclerosis proteins 1 and 2; GSK3β, glycogen synthase kinase 3β; MMP, matrix metallopeptidase; FKBP12, FK506-binding protein; PIP2, phosphatidylinositol 4,5 biphosphate; PDK1, phosphoinositol-dependent-kinase; PtdIns(3,4,5)P3, Phosphatidylinositol (3,4,5)-trisphosphate.


1 August 2023
Verified
Other
Open access
SMSahar Mafi
Sahar Mafi
EAElham Ahmadi
Elham Ahmadi
EMEileen Meehan
Eileen Meehan
Catharina ChiariCatharina Chiari
Catharina Chiari
BMBehzad Mansoori
Behzad Mansoori
Davood RostamzadehDavood Rostamzadeh
Davood Rostamzadeh
Supplementary Fig. S1. The structure of mTOR complexes and overview of the PI3K/AKT/mTOR signaling pathway. The mTOR signaling pathway is implicated in a variety of major cellular processes, from cell growth to apoptosis. mTOR nucleates at least two distinct multi-protein complexes, mTORC1 and mTORC2. mTORC1 activation occurs in the response of growth factors through PI3K/Akt and RAS/MAPK pathways. Human mTOR can assemble at least two larges, physically, and functionally distinct polyprotein complexes, mTORC1, and mTORC2. mTORC1 and mTORC2 share several common proteins, including the catalytic subunit mTOR, mLST8 and DEPTOR, and Tel2/Tti1 complex. In addition, each complex has specific proteins. The activity of mTORC1 is regulated by multiple signals, including nutrient availability such as amino acids (leucine, arginine, and glutamine), intracellular energy level (Low ATP/High AMP), and extracellular growth factors such as insulin and cytokine receptors. A receptor-mediated activation of PI3K leads to PIP3 being produced from PIP2. PIP3 then promoted the recruitment of PDK1, AKT, and mTORC2 complex, facilitating the phosphorylation and full activation of AKT at Thr308 and Ser473 via PDK1 and mTORC2, respectively. Activated AKT phosphorylates TSC2 and induces the dissociation of TSC1 and TSC2 complex, which results in the dissociation of TSC2 from lysosomes and loss of their inhibitory action on RHEB/mTORC1 axis. Upon activation, mTOC1 promotes basic cellular events, including Cap-dependent translation, fatty acid synthesis, nucleoid acid synthesis, ribosomal biogenesis, metabolic reprogramming to support rapid cancer cell growth and survival, metastasis and invasion, and angiogenesis. mTORC2 has different subcellular localization and phosphorylates and activates AGC kinase family members, including AKT at Ser473 (AKT-pSer473), SGK, and PKC in response to upstream signals such as IGF1. Similar to mTORC1, PI3K acts as a critical regulator of mTORC2 by inducing the binding of mTORC2 to the ribosome. mTOR, mammalian/mechanistic target of rapamycin; PI3K, phosphatidylinositol 3-kinase; RAPTOR, Regulatory associated protein of mTOR; PRAS40, Proline-rich AKT substrate 40ku; mLST8, Mammalian LST8, also called G protein b-subunit like protein; DEPTOR, DEP domain-containing-mTOR interacting protein; Tel2, Telomere maintenance 2; Tti1, Tel2-interacting protein 1; RICTOR, Rapamycin insensitive companion of mTOR; mSIN1, mitogen-activated protein kinase-associated protein 1; PROTOR, Protein observed with Rictor; SGK, serum glucose kinase; PKC, protein kinase C; IGF1; Insulin-like growth factor 1; AMPK, AMP-activated protein kinase; REDD1, regulated in development and DNA damage response 1; HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; PTEN, phosphatase and tensin homolog deleted on chromosome 10; NF-κB, nuclear factor-κB; ULK1, UNC-51-like kinase 1; 4E-BP1, initiation factor 4E-binding protein 1; RHEB, Ras homolog enriched in brain; TSC1 and TSC2, tuberous sclerosis proteins 1 and 2; GSK3β, glycogen synthase kinase 3β; MMP, matrix metallopeptidase; FKBP12, FK506-binding protein; PIP2, phosphatidylinositol 4,5 biphosphate; PDK1, phosphoinositol-dependent-kinase; PtdIns(3,4,5)P3, Phosphatidylinositol (3,4,5)-trisphosphate.